Current Report Filing (8-k)
September 27 2019 - 4:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported)
September 24, 2019
INTEC PHARMA LTD.
(Exact name of registrant as specified in
its charter)
Israel
|
001-37521
|
N/A
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
12 Hartom St.
Har Hotzvim
|
|
Jerusalem, Israel
|
9777512
|
(Address of principal executive offices)
|
(Zip Code)
|
+ 972-2-586-4657
|
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed since
last report)
|
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange
on which registered
|
Ordinary Shares, no, par value
|
|
NTEC
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 5.08
|
Shareholder Director Nominations.
|
On September 24, 2019,
the board of directors of Intec Pharma Ltd. (the “Company”) established December 2, 2019, as the date for the Company’s
2019 Annual Meeting of Shareholders (the “Annual Meeting”). Because this date is more than 30 days from the anniversary
of the 2018 Annual Meeting of Shareholders, updated deadlines apply for submission of shareholder proposals to be considered for
inclusion in the Company’s proxy materials for the Annual Meeting.
Shareholders who wish
to have a proposal considered for inclusion in the Company’s proxy materials for the Annual Meeting pursuant to Rule
14a-8 under the Securities and Exchange Act 1934, as amended, must ensure that such proposal is received on or before October
25, 2019 at the Company’s principal executive offices located at Intec Pharma Ltd., 12 Hartom St., Har
Hotzvim Jerusalem 9777512, Israel, Attention: Chief Financial Officer. The Company has determined this to be a reasonable
deadline for submission of shareholder proposals before it begins to print and mail its definitive proxy materials for the
Annual Meeting.
In accordance with the
requirements of Israeli law, shareholders who wish to bring business before the Annual Meeting other than pursuant to Rule 14a-8,
including director nominations, must ensure that written notice of such proposal is received at Intec Pharma Ltd., 12 Hartom St.,
Har Hotzvim Jerusalem 9777512, Israel, Attention: Chief Financial Officer on or before November 1, 2019.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: September 27, 2019
|
INTEC PHARMA LTD.
|
|
|
|
By:
|
/s/ Nir Sassi
|
|
|
Nir Sassi
|
|
|
Chief Financial Officer
|
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Sep 2023 to Sep 2024